Three cases of schizophrenia showing improvement after switching to blonanserin

Psychiatry and Clinical Neurosciences

Volumn 65, Issue 4, 2011, Pages 396-397

  Kurotaki, Naohiro ^a   Nobata, Hiroyuki ^b   Nonaka, Shunsuke ^b   Nishihara, Koji ^b   Ozawa, Hiroki ^a  

^a Department of Psychiatry   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ARIPIPRAZOLE; BIPERIDEN; BLONANSERIN; MUSCARINIC RECEPTOR; OLANZAPINE; RISPERIDONE;

ADULT; ANXIETY; AUDITORY HALLUCINATION; CASE REPORT; CHEST TIGHTNESS; DAILY LIFE ACTIVITY; DELUSION; DISEASE EXACERBATION; DROWSINESS; DRUG BINDING; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; HYPERSALIVATION; LETTER; MALE; PARANOID SCHIZOPHRENIA; PARKINSONISM; PHOTOSENSITIVITY; SCHIZOPHRENIA; SIDE EFFECT; SINUS TACHYCARDIA;

ADULT; ANTIPSYCHOTIC AGENTS; DELUSIONS; DOPAMINE ANTAGONISTS; HALLUCINATIONS; HUMANS; MALE; PIPERAZINES; PIPERIDINES; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 79959639720     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2011.02223.x     Document Type: Letter

References (3)

1. Murasaki M,. Preclinical characteristic and clinical positioning of blonanserin for schizophrenia. Jpn. J. Clin. Psychopharmacol. 2008; 11: 461-476 (in Japanese).
2. Murasaki M, Nishikawa H, Ishibashi T,. Dopamine-serotonin antagonist: receptor-binding profile of a novel antipsychotic blonanserin. Jpn. J. Clin. Psychopharmacol. 2008; 11: 845-854 (in Japanese).
3. Yang J, Bahk WM, Cho HS, et al,. Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin. Neuropharmacol. 2010; 33: 169-175.